How to Evaluate a Healthcare Device's Addressable Market

By Kevin Fernando · Sep 17, 2026 · 11 min read

Evaluating a healthcare device's addressable market requires defining the eligible patient population, mapping where the device fits in clinical care, confirming reimbursement coverage, estimating realistic adoption rates, and converting those inputs into revenue projections. The process moves beyond disease prevalence to account for clinical severity, treatment setting, payer coverage, and competitive adoption to estimate what fraction of the theoretical market will actually generate revenue.

A large patient population does not equal a large market. Cardiovascular disease affected an estimated 62 million people in the European Union in 2022, yet only a fraction of those patients meet the clinical criteria for any specific device, only some of those will have access to reimbursement, and only a portion of those will actually adopt the technology. The difference between theoretical addressable market and real revenue opportunity determines whether a device company can build a sustainable business.

Evaluating a healthcare device's addressable market requires moving beyond disease prevalence to systematically filter patients by clinical indication, disease stage, treatment setting, reimbursement coverage, and realistic adoption. This guide teaches the bottom-up methodology that investors, analysts, and entrepreneurs use to size device markets accurately and spot inflated projections.

What you'll be able to do

After working through this evaluation process, you will be able to estimate the realistic revenue opportunity for a healthcare device by converting clinical eligibility into an economically viable market size. You will learn to identify which assumptions most heavily influence the final number, test sensitivity to changes in those assumptions, and recognize when published market estimates are overstated. You will understand why devices with large eligible patient populations sometimes fail commercially and why smaller populations can support profitable businesses.

Define the patient population and clinical indication

The addressable market begins with a precise denominator: how many patients actually need this device and meet the clinical criteria for its use. This is not the same as disease prevalence. Start by narrowing from the broad disease category to the exact patient subset the device addresses, then filter further by disease stage, severity, comorbidities, and other clinical gates that determine candidacy.

Identify the specific diagnosis or clinical problem

Begin by defining the specific diagnosis or clinical problem, not the disease category. A device for atrial fibrillation is not a device for all cardiac arrhythmias. A device for moderate-to-severe osteoarthritis of the knee is not a device for all knee pain. The narrower the indication, the smaller the addressable market, but also the more defensible the clinical claim and the easier the reimbursement pathway.

Start with the device's regulatory indication. If the device is already approved or cleared, the indication statement defines the legal boundary of its use. If the device is in development, the target indication should be based on the clinical evidence and the company's development strategy. Write down the specific diagnosis, the anatomic location (if relevant), and the clinical problem the device solves. This becomes your starting denominator.

Account for severity, stage, or patient subgroups

Not all patients with the condition are candidates. Filter by disease stage, symptom severity, failed prior treatments, or comorbidities that affect eligibility. A device for end-stage heart failure addresses a smaller population than a device for all heart failure. A device for treatment-resistant depression addresses a smaller population than a device for all depression.

Review the clinical literature and the device's clinical trial inclusion and exclusion criteria. These define the population in which the device has been studied and is most likely to work. Patients outside those criteria may be ineligible due to safety concerns, lack of efficacy data, or contraindications. Document the clinical gates that narrow the population: disease stage, symptom severity, prior treatment history, organ function, age range, or other factors. Each gate shrinks the addressable market but increases the clinical defensibility and reimbursement likelihood.

Map the treatment pathway and clinical setting

Determine where in the care continuum the device is used and which healthcare settings actually deploy it. A device used only in tertiary referral centers reaches fewer patients than one used in primary care. A device that requires hospitalization reaches fewer patients than one that can be used in an outpatient clinic or at home.

Map the patient journey from diagnosis to treatment decision. At what point in that journey is the device indicated? Is it a first-line treatment, a second-line option after other treatments fail, or a salvage therapy for refractory cases? Each position in the pathway affects both the number of eligible patients and the adoption likelihood. A first-line device reaches more patients but faces more entrenched competition. A salvage therapy reaches fewer patients but may face less competition.

Identify the clinical settings where the device is deployed: hospital inpatient, hospital outpatient, ambulatory surgery center, physician office, urgent care, or home. Each setting has different infrastructure requirements, staffing models, and reimbursement mechanisms. A device that requires specialized equipment or training may be limited to academic medical centers or large hospitals, shrinking the addressable market to institutions with those resources.

Establish reimbursement and pricing constraints

Reimbursement is a higher bar than regulatory approval. A device can be safe and effective but still not generate revenue if payers do not cover it or if coverage is inadequate to support adoption. Identify whether payers will actually reimburse the device and at what price, which determines whether the addressable market is economically viable.

Check for existing reimbursement pathways

Determine if payers already reimburse similar devices or if your device requires new coverage decisions. If similar devices are already reimbursed, your device may fit into an existing Current Procedural Terminology (CPT) code or reimbursement pathway, accelerating coverage. If your device is novel, payers may require new evidence, a new CPT code, or a coverage decision, which delays reimbursement and increases uncertainty.

Research the reimbursement landscape for the clinical indication. Check whether Medicare (CMS) covers similar devices, at what price, and under what clinical conditions. Review private payer coverage policies for the major insurers in your target geography. If coverage already exists for similar devices, document the reimbursement amount and any coverage restrictions (prior authorization, quantity limits, patient cost-sharing). If coverage does not exist, research the evidence and approval requirements for new coverage. The average delay from FDA approval to CMS reimbursement is 4.7 years, and the entire new CPT code application process can take from 18 to 24 months, with evidence collection requiring 2 to 5 years. These timelines shrink the addressable market in the years immediately after regulatory approval.

Assess out-of-pocket barriers

Recognize when patient cost-sharing or lack of insurance coverage shrinks the addressable market. Even if a payer covers the device, patients may face high copayments, coinsurance, or deductibles that deter adoption. Patients without insurance or with very limited coverage may be unable to access the device regardless of clinical need.

Research the typical cost-sharing for similar devices in your target payer mix. If the device is used primarily in insured populations in developed healthcare systems, cost-sharing may be modest. If the device serves uninsured or underinsured populations, or if it is used in lower-income countries, out-of-pocket cost becomes a major barrier. Document the expected patient out-of-pocket cost and assess whether it is a realistic barrier to adoption. A device priced at $8,000 with payer reimbursement of $10,000 may not be adopted by hospitals if the reimbursement does not cover the full cost of care, shrinking the addressable market despite regulatory approval and payer coverage.

Quantify adoption and penetration assumptions

Estimate what fraction of eligible patients will actually receive the device, accounting for clinician adoption, competing alternatives, and market maturity. This is often the most uncertain input in addressable market sizing and the most common source of overestimation.

Adoption is not binary. Even when a device is clinically indicated, reimbursed, and available, clinicians may not adopt it immediately or at all. Adoption depends on clinician awareness, training, confidence in the technology, habit and inertia, competing alternatives, and the strength of clinical evidence. Research suggests that on average, it takes up to 17 years for only 14% of published evidence to translate into practice, illustrating the lag between clinical proof and clinical adoption.

Start with an adoption curve. Early adopters (typically 2-5% of eligible clinicians) adopt quickly if the device solves a clear clinical problem. Early majority adopt as evidence accumulates and peer adoption increases. Late majority adopt only after the technology is established and competing alternatives decline. Laggards (remaining clinicians) may never adopt. For a mature device in a stable market, penetration might reach a substantial portion of eligible patients. For a new device in the first five years after launch, penetration is typically much lower.

Document competing alternatives. If the device competes against an established standard of care, adoption is slower and penetration is lower. If the device addresses an unmet need with no good alternative, adoption can be faster. Estimate the market share your device will capture relative to competitors, accounting for clinical superiority, ease of use, reimbursement, and clinician relationships.

Calculate total addressable market and serviceable market

Convert patient population, reimbursement, and adoption assumptions into a revenue-based market size estimate. This requires two calculations: total addressable market (TAM), which represents the maximum revenue if the device captured 100% of eligible patients at full reimbursement, and serviceable addressable market (SAM), which narrows TAM to the realistic market the company can reach.

Build the total addressable market (TAM)

Estimate maximum revenue if the device captured 100% of eligible patients at full reimbursement. Start with the eligible patient population (after filtering by clinical indication, disease stage, and treatment setting). Multiply by the annual treatment frequency (how many times per year the device is used per patient, or how many patients are treated annually). Multiply by the reimbursement amount per treatment or per patient.

For example, suppose a device is indicated for 500,000 eligible patients annually in a specific geography. If the device is used once per patient per year and reimbursement is $5,000 per use, the TAM is 500,000 times $5,000, or $2.5 billion. This represents the maximum revenue if every eligible patient received the device at full reimbursement.

TAM is useful as a ceiling, but it is rarely achieved.

Adjust to serviceable addressable market (SAM)

Narrow TAM to the realistic market the company can reach given geography, competitive position, and adoption constraints. SAM accounts for the fact that the company will not reach all eligible patients, reimbursement will vary, and adoption will be incomplete.

Start with TAM and apply realistic constraints. First, narrow by geography if the company is not operating globally. If the company operates in North America only, and North America represents a certain fraction of the global eligible population, apply that geographic constraint. Second, apply a market share assumption based on competitive position. If the company is a new entrant competing against established alternatives, market share might be 10-20% of the addressable market. If the company has a differentiated product or first-mover advantage, market share might be higher. Third, apply an adoption penetration assumption based on the adoption curve and competitive dynamics. If the device is new, penetration might be 5-10% in year one, growing to 20-30% by year five. If the device is mature, penetration might be 40-60%.

For the example above, suppose the company operates in North America, which represents 40% of the global eligible population (200,000 patients). Suppose the company's market share is 15% due to competition (30,000 patients). Suppose adoption penetration is 25% in a mature market (7,500 patients actually treated).

Identify and stress-test key assumptions

Recognize which inputs most heavily influence the final market size and test sensitivity to changes in those assumptions. Market sizing is not a point estimate; it is a range bounded by optimistic and pessimistic scenarios.

Identify the three to five inputs that most heavily drive the final market size. For most devices, these are: the eligible patient population, the reimbursement amount, the adoption penetration, and the market share. For each key input, estimate a base case, an optimistic case (higher adoption, higher reimbursement, larger population), and a pessimistic case (lower adoption, lower reimbursement, smaller population).

Calculate SAM under each scenario. The pessimistic scenario represents the downside risk if adoption is slow, reimbursement is lower than expected, or competitive pressure is higher. The optimistic scenario represents the upside if adoption accelerates, reimbursement is higher, or the company gains market share. The base case represents your best estimate given current information. This range (pessimistic to optimistic) is more honest than a single point estimate and helps stakeholders understand the uncertainty in the projection.

Recognize common pitfalls in device market sizing

Learn where addressable market estimates typically fail and how to spot inflated or unrealistic projections. These pitfalls are common in company presentations, venture pitches, and published market research.

Overestimating adoption and penetration

The most common error is assuming adoption will be faster and more complete than historical precedent supports. Company projections often assume that eligible patients will adopt the device within a few years, reaching 50% or higher penetration. Real-world adoption is slower, driven by clinician inertia, competing alternatives, reimbursement delays, and the time required to train clinicians and build infrastructure.

When evaluating a market sizing projection, ask: What is the basis for the adoption curve? Is it based on historical adoption of similar devices, or is it an optimistic assumption? If the company is projecting faster adoption than historical precedent, what is different about this device or this market? Be skeptical of projections that assume rapid, sustained adoption without acknowledging the barriers to clinician behavior change.

Ignoring reimbursement friction

The second common error is assuming reimbursement will be automatic or will occur quickly. Many market sizing projections assume that FDA approval or clinical evidence will lead to immediate payer coverage at the device's list price. In reality, reimbursement requires separate evidence, new CPT codes, and coverage decisions that take years to complete. During that period, the addressable market is zero or very small.

When evaluating a market sizing projection, ask: What is the reimbursement status today? Is the device already covered by major payers, or does it require new coverage decisions? If coverage is pending, what is the timeline for coverage? What is the evidence required for coverage? Is the company's clinical trial designed to generate that evidence? If reimbursement is uncertain or delayed, the addressable market in the near term is much smaller than the long-term potential.

Conflating incidence with addressable market

The third common error is using disease incidence or prevalence as a proxy for addressable market. Incidence refers to the occurrence of new cases of disease or injury in a population over a specified period of time. Prevalence is the proportion of the population with a condition at a specific point in time or during a period of time. Neither is the same as addressable market.

For example, if a town of 10,000 people reports 50 new cases of the flu in January, the incidence for that month is 50 per 10,000 people. But not all 50 cases require a specific device. Only patients meeting clinical criteria, in the right treatment setting, with access to reimbursement, and willing to adopt the technology represent addressable market. A market sizing projection that uses disease incidence or prevalence without filtering for clinical indication, disease stage, reimbursement, and adoption is overstated by an order of magnitude or more.

Do this automatically

Evaluating a healthcare device's addressable market requires manually filtering patient populations through clinical eligibility criteria, mapping treatment pathways across care settings, and applying reimbursement constraints, a multi-step calculation that grows more complex as you layer in disease severity, prior treatment history, and geographic variation in adoption. Software can systematize this filtering process, allowing you to test assumptions across different patient subgroups and reimbursement scenarios without rebuilding the analysis each time. Healthcare research runs this kind of analysis end to end and cites every figure back to its original source, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.

Start your first report and run it on something you already know well.

This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.